BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38072850)

  • 1. Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.
    Tosoni L; Liberi M; Morelli G; Zannier ME; Lazzarotto D; Filì C; Simeone E; Battaglia G; Callegari C; Fanin M; Damiani D; Fanin R; Tiribelli M
    Ann Hematol; 2024 Feb; 103(2):443-448. PubMed ID: 38072850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.
    Santoro M; Accurso V; Mancuso S; Carlisi M; Raso S; Tarantino G; Di Piazza F; Perez A; Russo A; Siragusa S
    Hematol Oncol; 2019 Oct; 37(4):434-437. PubMed ID: 31465530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic risk correlates with mutational status in true essential thrombocythemia.
    Bertozzi I; Peroni E; Coltro G; Bogoni G; Cosi E; Santarossa C; Fabris F; Randi ML
    Eur J Clin Invest; 2016 Aug; 46(8):683-9. PubMed ID: 27271054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia.
    Hashimoto Y; Nakamae H; Tanaka T; Omura H; Horiuchi M; Yoshimura T; Takakuwa T; Mugitani A; Hirose A; Nakamae M; Koh H; Hino M
    Eur J Haematol; 2018 Oct; 101(4):508-513. PubMed ID: 29971894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Garcia-Pallarols F; Longarón R; Ancochea À; Besses C
    Med Clin (Barc); 2015 Mar; 144(6):247-53. PubMed ID: 25192581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients.
    Fu R; Xuan M; Lv C; Zhang L; Li H; Zhang X; Zhang D; Sun T; Xue F; Liu X; Liang H; Zhang L; Yang R
    Eur J Haematol; 2014 Jun; 92(6):502-9. PubMed ID: 24460750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
    Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
    Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service.
    Navarro LM; Trufelli DC; Bonito DR; Del Giglio A; Bollmann PW
    Rev Assoc Med Bras (1992); 2016 Oct; 62(7):647-651. PubMed ID: 27925044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.
    Haider M; Gangat N; Lasho T; Abou Hussein AK; Elala YC; Hanson C; Tefferi A
    Am J Hematol; 2016 Jun; 91(4):390-4. PubMed ID: 26799697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
    Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
    Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of the revised International Prognostic Score of Thrombosis for essential thrombocythemia (IPSET-thrombosis) in a cohort of 746 Chinese adult patients].
    Fu RF; Li HY; Xue F; Liu XF; Liu W; Huang YT; Chen YF; Zhang LY; Zhang L; Yang RC
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):92-96. PubMed ID: 28279030
    [No Abstract]   [Full Text] [Related]  

  • 12. IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort.
    Sevindik OG; Mersin S; Katgi A; Tunali S; Solmaz SM; Acar C; Alacacioglu I; Piskin O; Ozcan MA; Demirkan F; Undar B; Ozsan GH
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e101-4. PubMed ID: 25790738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study.
    Saelue P; Thongsukhsai P
    J Thromb Thrombolysis; 2023 Apr; 55(3):527-535. PubMed ID: 36652138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.
    Finazzi G; Carobbio A; Guglielmelli P; Cavalloni C; Salmoiraghi S; Vannucchi AM; Cazzola M; Passamonti F; Rambaldi A; Barbui T
    Blood; 2014 Oct; 124(16):2611-2. PubMed ID: 25323688
    [No Abstract]   [Full Text] [Related]  

  • 15. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.
    Guglielmelli P; Carobbio A; Rumi E; De Stefano V; Mannelli L; Mannelli F; Rotunno G; Coltro G; Betti S; Cavalloni C; Finazzi MC; Thiele J; Cazzola M; Vannucchi AM; Barbui T
    Blood Cancer J; 2020 Feb; 10(2):21. PubMed ID: 32098944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
    Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
    Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
    Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
    Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
    Pérez Encinas MM; Sobas M; Gómez-Casares MT; Abuin Blanco A; Noya Pereira MS; Raya JM; Andrade-Campos MM; Álvarez Larrán A; Lewandowski K; Łukasz S; Hernández Boluda JC; Ferrer-Marín F; Fox ML; Gołos A; Gasior Kabat M; Magro Mazo E; Czyż A; Martín Martín A; Bellosillo Paricio B; Quinteiro García C; González Martín JM; Stuckey R
    Eur J Haematol; 2021 Mar; 106(3):371-379. PubMed ID: 33275803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study.
    Stuckey R; Ianotto JC; Santoro M; Czyż A; Perez Encinas MM; Gómez-Casares MT; Noya Pereira MS; de Nałęcz AK; Gołos A; Lewandowski K; Szukalski Ł; González-Martín JM; Wróbel T; Sobas MA
    Br J Haematol; 2022 Oct; 199(1):86-94. PubMed ID: 35906782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.